The M358R variant of α1-proteinase inhibitor inhibits coagulation factor VIIa

Biochemical and Biophysical Research Communications

Volumn 470, Issue 3, 2016, Pages 710-713

  Sheffield, William P ^a,b   Bhakta, Varsha ^a  

^a CANADIAN BLOOD SERVICES   (Canada)

^b MCMASTER UNIVERSITY   (Canada)

Author keywords

Alpha 1 proteinase inhibitor; Antithrombin; Blood coagulation; FVIIa; Heparin; Serpins

Indexed keywords

ALPHA1 PROTEINASE INHIBITOR III; ANTITHROMBIN; BLOOD CLOTTING FACTOR 7A; HEPARIN; ALPHA 1 ANTITRYPSIN; THROMBOPLASTIN;

ARTICLE; BLEEDING TENDENCY; GENETIC VARIABILITY; HUMAN; KINETICS; PRIORITY JOURNAL; PROTEIN DENATURATION; RATE CONSTANT; WILD TYPE; ANTAGONISTS AND INHIBITORS; BLOOD CLOTTING; GENETIC VARIATION; GENETICS; METABOLISM; PHYSIOLOGY; STRUCTURE ACTIVITY RELATION;

ALPHA 1-ANTITRYPSIN; BLOOD COAGULATION; FACTOR VIIA; GENETIC VARIATION; HUMANS; KINETICS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBOPLASTIN;

EID: 84957547722     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2016.01.069     Document Type: Article

References (30)

1. J.A. Huntington Serpin structure, function and dysfunction J. Thromb. Haemost. 9 Suppl 1 2011 26 34
2. M.C. Owen, S.O. Brennan, J.H. Lewis, and R.W. Carrell Mutation of antitrypsin to antithrombin. alpha 1-antitrypsin Pittsburgh (358 Met leads to Arg), a fatal bleeding disorder N. Engl. J. Med. 309 1983 694 698
3. P.C. Hopkins, R.N. Pike, and S.R. Stone Evolution of serpin specificity: cooperative interactions in the reactive-site loop sequence of antithrombin specifically restrict the inhibition of activated protein C J. Mol. Evol. 51 2000 507 515
4. C.F. Scott, R.W. Carrell, C.B. Glaser, F. Kueppers, J.H. Lewis, and R.W. Colman Alpha-1-antitrypsin-Pittsburgh. A potent inhibitor of human plasma factor XIa, kallikrein, and factor XIIf J. Clin. Investig. 77 1986 631 634
5. M.J. Heeb, R. Bischoff, M. Courtney, and J.H. Griffin Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358 J. Biol. Chem. 265 1990 2365 2369
6. D. Vidaud, J. Emmerich, M. Alhenc-Gelas, J. Yvart, J.N. Fiessinger, and M. Aiach Met 358 to Arg mutation of alpha 1-antitrypsin associated with protein C deficiency in a patient with mild bleeding tendency J. Clin. Investig. 89 1992 1537 1543
7. B. Hua, L. Fan, Y. Liang, Y. Zhao, and E.G. Tuddenham Alpha1-antitrypsin Pittsburgh in a family with bleeding tendency Haematologica 94 2009 881 884
8. J.H. Lawson, S. Butenas, N. Ribarik, and K.G. Mann Complex-dependent inhibition of factor VIIa by antithrombin III and heparin J. Biol. Chem. 268 1993 767 770
9. L.V. Rao, S.I. Rapaport, and A.D. Hoang Binding of factor VIIa to tissue factor permits rapid antithrombin III/heparin inhibition of factor VIIa Blood 81 1993 2600 2607
10. M.L. Filion, V. Bhakta, L.H. Nguyen, P.S. Liaw, and W.P. Sheffield Full or partial substitution of the reactive center loop of alpha-1-proteinase inhibitor by that of heparin cofactor II: P1 Arg is required for maximal thrombin inhibition Biochemistry 43 2004 14864 14872
11. P. Margaritis, E. Roy, A. Faella, H.D. Downey, L. Ivanciu, G. Pavani, S. Zhou, R.M. Bunte, and K.A. High Catalytic domain modification and viral gene delivery of activated factor VII confers hemostasis at reduced expression levels and vector doses in vivo Blood 117 2011 3974 3982
12. W.P. Sheffield, L.J. Eltringham-Smith, V. Bhakta, and S. Gataiance Reduction of thrombus size in murine models of thrombosis following administration of recombinant alpha1-proteinase inhibitor mutant proteins Thromb. Haemost. 107 2012 972 984
13. S.T. Olson, R. Swanson, E. Raub-Segall, T. Bedsted, M. Sadri, M. Petitou, J.P. Herault, J.M. Herbert, and I. Bjork Accelerating ability of synthetic oligosaccharides on antithrombin inhibition of proteinases of the clotting and fibrinolytic systems. Comparison with heparin and low-molecular-weight heparin Thromb. Haemost. 92 2004 929 939
14. S.T. Olson, I. Bjork, R. Sheffer, P.A. Craig, J.D. Shore, and J. Choay Role of the antithrombin-binding pentasaccharide in heparin acceleration of antithrombin-proteinase reactions. Resolution of the antithrombin conformational change contribution to heparin rate enhancement J. Biol. Chem. 267 1992 12528 12538
15. J.A. Huntington Thrombin inhibition by the serpins J. Thromb. Haemost. 11 Suppl 1 2013 254 264
16. I. Martinez-Martinez, A. Ordonez, S. Pedersen, M.E. de la Morena-Barrio, J. Navarro-Fernandez, S.R. Kristensen, A. Minano, J. Padilla, V. Vicente, and J. Corral Heparin affinity of factor VIIa: implications on the physiological inhibition by antithrombin and clearance of recombinant factor VIIa Thromb. Res. 127 2011 154 160
17. S.A. Silverberg, Y. Nemerson, and M. Zur Kinetics of the activation of bovine coagulation factor X by components of the extrinsic pathway. Kinetic behavior of two-chain factor VII in the presence and absence of tissue factor J. Biol. Chem. 252 1977 8481 8488
18. W. Ruf, M.W. Kalnik, T. Lund-Hansen, and T.S. Edgington Characterization of factor VII association with tissue factor in solution. High and low affinity calcium binding sites in factor VII contribute to functionally distinct interactions J. Biol. Chem. 266 1991 15719 15725
19. S.P. Bajaj, A.E. Schmidt, S. Agah, M.S. Bajaj, and K. Padmanabhan High resolution structures of p-aminobenzamidine- and benzamidine-VIIa/soluble tissue factor: unpredicted conformation of the 192-193 peptide bond and mapping of Ca2+, Mg2+, Na+, and Zn2+ sites in factor VIIa J. Biol. Chem. 281 2006 24873 24888
20. K. Vadivel, and S.P. Bajaj Structural biology of factor VIIa/tissue factor initiated coagulation Front. Biosci. (Landmark Ed. 17 2012 2476 2494
21. A. Dementiev, M. Simonovic, K. Volz, and P.G. Gettins Canonical inhibitor-like interactions explain reactivity of alpha1-proteinase inhibitor Pittsburgh and antithrombin with proteinases J. Biol. Chem. 278 2003 37881 37887
22. S.C. Bock, K.L. Wion, G.A. Vehar, and R.M. Lawn Cloning and expression of the cDNA for human antithrombin III Nucleic Acids Res. 10 1982 8113 8125
23. R.K. Kaul, B. Hildebrand, S. Roberts, and P. Jagadeeswaran Isolation and characterization of human blood-coagulation factor X cDNA Gene 41 1986 311 314
24. F.S. Hagen, C.L. Gray, P. O'Hara, F.J. Grant, G.C. Saari, R.G. Woodbury, C.E. Hart, M. Insley, W. Kisiel, K. Kurachi, and E.W. Davie Characterization of a cDNA coding for human factor VII Proc. Natl. Acad. Sci. U. S. A. 83 1986 2412 2416
25. I. Salemink, J. Franssen, G.M. Willems, H.C. Hemker, and T. Lindhout Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition J. Biol. Chem. 274 1999 28225 28232
26. G. Murano, L. Williams, M. Miller-Andersson, D.L. Aronson, and C. King Some properties of antithrombin-III and its concentration in human plasma Thromb. Res. 18 1980 259 262
27. W.F. Novotny, S.G. Brown, J.P. Miletich, D.J. Rader, and G.J. Broze Jr. Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples Blood 78 1991 387 393
28. L. Spiezia, V. Rossetto, E. Campello, S. Gavasso, B. Woodhams, D. Tormene, and P. Simioni Factor VIIa-antithrombin complexes in patients with arterial and venous thrombosis Thromb. Haemost. 103 2010 1188 1192
29. G.C. Price, S.A. Thompson, and P.C. Kam Tissue factor and tissue factor pathway inhibitor Anaesthesia 59 2004 483 492
30. U. Hedner Recombinant factor VIIa: its background, development and clinical use Curr. Opin. Hematol. 14 2007 225 229